Aquatic Capital Management LLC Grows Position in Twist Bioscience Co. (NASDAQ:TWST)

Aquatic Capital Management LLC raised its holdings in shares of Twist Bioscience Co. (NASDAQ:TWST - Free Report) by 13.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 61,100 shares of the company's stock after purchasing an additional 7,100 shares during the quarter. Aquatic Capital Management LLC owned approximately 0.10% of Twist Bioscience worth $2,839,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Barclays PLC lifted its holdings in shares of Twist Bioscience by 214.8% in the third quarter. Barclays PLC now owns 153,039 shares of the company's stock worth $6,913,000 after buying an additional 104,420 shares in the last quarter. Avanza Fonder AB purchased a new stake in shares of Twist Bioscience in the fourth quarter worth about $1,059,000. Principal Financial Group Inc. lifted its holdings in shares of Twist Bioscience by 67.5% in the third quarter. Principal Financial Group Inc. now owns 205,864 shares of the company's stock worth $9,301,000 after buying an additional 82,953 shares in the last quarter. Oddo BHF Asset Management Sas purchased a new stake in shares of Twist Bioscience in the third quarter worth about $3,302,000. Finally, Vanguard Group Inc. lifted its holdings in shares of Twist Bioscience by 3.4% in the fourth quarter. Vanguard Group Inc. now owns 5,807,183 shares of the company's stock worth $269,860,000 after buying an additional 189,791 shares in the last quarter.

Insider Buying and Selling

In other Twist Bioscience news, CEO Emily M. Leproust sold 1,726 shares of the company's stock in a transaction dated Thursday, March 20th. The shares were sold at an average price of $41.68, for a total value of $71,939.68. Following the sale, the chief executive officer now owns 660,966 shares in the company, valued at approximately $27,549,062.88. This represents a 0.26 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Patrick John Finn sold 2,058 shares of the company's stock in a transaction dated Wednesday, April 23rd. The stock was sold at an average price of $39.99, for a total transaction of $82,299.42. Following the completion of the sale, the chief operating officer now owns 265,460 shares in the company, valued at approximately $10,615,745.40. This trade represents a 0.77 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 22,432 shares of company stock valued at $1,038,170 over the last three months. Corporate insiders own 3.01% of the company's stock.

Twist Bioscience Stock Performance

Shares of NASDAQ:TWST opened at $39.90 on Tuesday. The company has a market cap of $2.38 billion, a price-to-earnings ratio of -11.80 and a beta of 2.34. The company has a 50-day moving average price of $39.51 and a 200-day moving average price of $44.26. The company has a current ratio of 4.96, a quick ratio of 4.62 and a debt-to-equity ratio of 0.03. Twist Bioscience Co. has a 12 month low of $30.32 and a 12 month high of $60.90.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last released its quarterly earnings results on Monday, February 3rd. The company reported ($0.53) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.62) by $0.09. Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. The company had revenue of $88.70 million during the quarter, compared to the consensus estimate of $86.96 million. During the same period in the prior year, the firm earned ($0.75) earnings per share. Twist Bioscience's revenue was up 24.1% on a year-over-year basis. As a group, equities analysts anticipate that Twist Bioscience Co. will post -2.12 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on TWST shares. Barclays decreased their price objective on shares of Twist Bioscience from $58.00 to $45.00 and set an "overweight" rating on the stock in a research report on Thursday, April 10th. JPMorgan Chase & Co. upped their price objective on shares of Twist Bioscience from $35.00 to $40.00 and gave the stock an "underweight" rating in a research report on Tuesday, February 4th. Guggenheim set a $50.00 price target on shares of Twist Bioscience in a research report on Friday, March 28th. Scotiabank restated an "outperform" rating on shares of Twist Bioscience in a report on Tuesday, February 4th. Finally, Robert W. Baird increased their target price on shares of Twist Bioscience from $48.00 to $54.00 and gave the company an "outperform" rating in a report on Tuesday, February 4th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eight have given a buy rating to the company's stock. According to data from MarketBeat, Twist Bioscience currently has an average rating of "Moderate Buy" and a consensus price target of $52.80.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.

Want to see what other hedge funds are holding TWST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Twist Bioscience Co. (NASDAQ:TWST - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.